The estimated Net Worth of Corazon (Corsee) D. Sanders is at least $584 Tisíc dollars as of 2 July 2024. Corazon Sanders owns over 584 units of Molecular Templates Inc stock worth over $16,452 and over the last 5 years he sold MTEM stock worth over $304,759. In addition, he makes $263,073 as Independent Director at Molecular Templates Inc.
Corazon has made over 5 trades of the Molecular Templates Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 584 units of MTEM stock worth $23,932 on 2 July 2024.
The largest trade he's ever made was selling 1,737 units of Molecular Templates Inc stock on 10 June 2024 worth over $71,391. On average, Corazon trades about 276 units every 22 days since 2019. As of 2 July 2024 he still owns at least 12,009 units of Molecular Templates Inc stock.
You can see the complete history of Corazon Sanders stock trades at the bottom of the page.
Dr. Corazon Dating Sanders Ph.D. serves as Independent Director of the Company. Dr. Sanders serves as a Strategic Advisor to the Global Development Group of Bristol Myers Squibb, a position she has held since November 2019. Previously, Dr. Sanders served as Strategic Advisor to the Office of the Celgene Chief Medical Officer, since March 2018, ensuring effective integration of Juno Therapeutics’ Development Organization into the Celgene Organization, specifically the unique CAR T aspects, advising the label-enabling CAR T legacy Juno program (JCAR017), and advising the Chief Medical Officer and the Chief Medical Officer’s leadership team in evolving the clinical development organization. From January 2017 to March 2018, Dr. Sanders was a Member of the Juno Therapeutics Executive Committee as Executive Vice President of Development Operations, with responsibilities for strategic operations, quantitative sciences, biosample and clinical operations. Dr. Sanders was a Member of the Genentech/Roche Late Stage Portfolio Committee from 2011 to 2017, and Global Head of the Genentech/Roche Late Stage Clinical Operations from 2012 to 2017, with responsibility for leading nearly 2,500 employees, across 5 strategic and 20 local country sites, in planning and conducting global development and local clinical trials in over 70 countries. She was Global Head of the Genentech/Roche Biometrics group from 2009 to 2012, and Genentech Head of DATA (Design, Analysis, Technology & Administration) prior to the Roche acquisition. Earlier in her career, she was employed at Schering-Plough Research Institute and at Centocor Inc., primarily in statistician and biomedical operations roles
As the Independent Director of Molecular Templates Inc, the total compensation of Corazon Sanders at Molecular Templates Inc is $263,073. There are 8 executives at Molecular Templates Inc getting paid more, with Eric Poma having the highest compensation of $1,733,740.
Corazon Sanders is 63, he's been the Independent Director of Molecular Templates Inc since 2019. There are 2 older and 17 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.
Corazon's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.
Over the last 7 years, insiders at Molecular Templates Inc have traded over $22,993,582 worth of Molecular Templates Inc stock and bought 14,744,530 units worth $82,519,716 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., David Hirsch a Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of $532,718. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth $587,500.
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
Molecular Templates Inc executives and other stock owners filed with the SEC include: